

First Total Synthesis of Dihydroxerulin, a Potent Inhibitor of the Biosynthesis of Cholesterol**

Konrad Siegel and Reinhard Brückner*


Dedicated to Professor Wolfgang Steglich on the occasion of his 65th birthday

Abstract: Dihydroxerulin (**1**) is a noncytotoxic inhibitor of cholesterol biosynthesis. In spite of being achiral and devoid of OH groups, it was synthesized efficiently (12 steps, 6 steps in the longest linear sequence) from the optically active, polyhydroxylated sugar lactone **6**. Our synthesis follows the strategy of Scheme 2 and illustrates with the β -elimination **10** \rightarrow (*Z*)-**9** a novel general approach to γ -alkylidenebutenolides with stereopure $C_\beta=C$ bonds. The enol triflate (*Z*)-**9** was hydrogenolyzed to lactone (*Z*)-**11** under very mild conditions. A Wittig reaction with the derived aldehyde (*Z*)-**13** delivered 30% of the title compound. Its 800 MHz ^1H NMR spectrum revealed that the $C^8=C^9$ bond of synthetic, and therefore also natural, **1** is *trans*-substituted.

Keywords: butenolides • lactones • natural products • stereoselective synthesis • structure elucidation

Introduction

Many natural products are γ -alkylidenebutenolides^[1, 2] but only a few of them contain no additional ring substituent.^[3] A prominent example of such a compound is dihydroxerulin (**1**; Scheme 1). It was isolated from *Xerula melanotricha* Dörfelt and structurally elucidated (except for the configuration of the $C^8=C^9$ double bond) by Steglich, Anke, et al.^[4] Dihydroxerulin is a noncytotoxic inhibitor of cholesterol biosynthesis



Scheme 1. Dihydroxerulin (**1**) and its derivatives, with numbering scheme.

($\text{ID}_{50} = 1 \mu\text{g g}^{-1}$), preventing the incorporation of [^{14}C]acetate, but not of [^{14}C]mevalonic acid, into cholesterol produced from HeLa S3 cells.^[4] Dihydroxerulin was only isolated in 90:10–65:35 mixtures with xerulin (**2**). Nonetheless, 500 MHz ^1H NMR spectra of these mixtures in CDCl_3 allowed to determine the constitution of the major component entirely and in addition almost all of its stereochemistry. The only unknown remained the configuration of the $C^8=C^9$ bond, due to severe signal overlap. However, this configuration was suspected to be *trans*, because compounds **1** and **2** cooccurred with xerulinic acid (**3**).^[4] The latter displays nonsuperimposed signals for 8-H and for 9-H and a mutual first-order splitting by $J_{8,9} = 14.9 \text{ Hz}$; this is a typical value for J_{trans} .


The unique structure of the presently known members **1–3** of the xerulin family, the pronounced depression of cholesterol levels which they cause, and the hope that structural analogues might turn out to be even more biologically active make these and similar compounds attractive targets for synthetic chemists. We initiated such a program ourselves and present in the following the first laboratory synthesis of dihydroxerulin (**1**). In addition, a computer analysis of the 800 MHz ^1H NMR spectrum of synthetic **1** in C_6D_6 corroborated the hitherto only suspected (*vide supra*) 8-*trans* configuration.

It is important that our synthesis makes the particular target molecule **1** accessible by an approach that we hope will become a general strategy for the stereocontrolled production of γ -alkylidene butenolides with or without α -substituents.^[5] The key steps are stereospecific *anti*-selective eliminations of water from the γ -(1-hydroxyalkyl)-substituted 2(*5H*)-furanones **4** or *iso*-**4**, be they racemic or enantiopure, depicted in

[*] Prof. Dr. R. Brückner, Dipl.-Chem. K. Siegel
Institut für Organische Chemie der Georg-August-Universität
Tammannstr. 2, D-37077 Göttingen (Germany)
Fax: (+49) 551-392944
E-mail: rbrueck@gwdg.de

[**] First presented at the 9th IUPAC Symposium Organometallic Chemistry Directed Towards Organic Synthesis (OMCOS 9) in Göttingen, July 20–25, 1997 (poster 453).

Scheme 2. Furanones of generic structure **4** give γ -alkylidenebutenolides (*Z*)-**5** if they eliminate *anti* while, under the same proviso, the diastereomeric furanones *iso*-**4** give the




Scheme 2. Stereospecific *anti*-selective eliminations of water from the γ -(1-hydroxyalkyl)-substituted 2(5*H*)-furanones **4** and *iso*-**4**.

isomeric butenolides (*E*)-**5**. To the best of our knowledge, β -eliminations have so far only allowed access to γ -alkylidenebutenolides with little^[6] or with no stereoselectivity at all^[7] (exception: ref. [8]); it did not matter whether the elimination step was performed separately^[6b, 7a,c] or took place in situ.^[6a,c,d, 7b]

Results and Discussion

Our synthesis of dihydroxerulin started from L-gulono-1,4-lactone (**6**; Scheme 3).^[9] Protection of the primary alcohol function^[10] delivered the silylated lactone **7**. All free OH groups of this compound were sulfonylated and two of them subsequently eliminated by treatment with 3.3 equiv of triflic

Abstract in German: Dihydroxerulin (**1**) ist ein nichtcytotoxischer Inhibitor der Cholesterin-Biosynthese. Obwohl diese Verbindung achiral ist und keine OH-Gruppen enthält, wurde sie in sehr effizienter Weise (12 Stufen, 6 Stufen in der längsten linearen Sequenz) aus dem optisch aktiven und hochhydroxylierten Zuckerlacton **6** synthetisiert. Die von uns realisierte Route folgt der in Schema 2 dargelegten Synthesestrategie. Sie illustriert am Beispiel der β -Eliminierung **10** \rightarrow (*Z*)-**9** einen neuartigen generellen Zugang zu γ -Alkylidenebutenoliden, die eine stereochemisch definierte $C_{\gamma}=C$ -Bindung von frei wählbarer Konfiguration enthalten. Das Enoltriflat (*Z*)-**9** wurde unter sehr milden Bedingungen zum triflatfreien Lacton (*Z*)-**11** hydrogenolysiert. Eine Wittig-Reaktion mit dem davon abgeleiteten Aldehydolacton (*Z*)-**13** und dem Ylid des stark ungesättigten Phosphoniumsalzes **21** lieferte die Titelverbindung in 30% Ausbeute. Deren 800-MHz-¹H-NMR-Spektrum zeigte, daß die $C^8=C^9$ -Bindung von synthetischem und mithin auch von natürlichem **1** *trans*-substituiert ist.




Scheme 3. a) *t*BuMe₂SiCl (0.95 equiv), imidazole (2.0 equiv), DMF, -30°C , 1 h; \rightarrow RT, 2 h; 58%; b) pyridine (5.0 equiv), Tf₂O (3.3 equiv), CH₂Cl₂, -85°C , 40 min; \rightarrow -20°C , 80 min; \rightarrow -10°C , 90 min; 85% (*Z*:*E* > 99:1); c) LiCl (3.0 equiv), NiCl₂(PPh₃)₂ (2 mol%), THF, RT, 15 s; Bu₃SnH (1.1 equiv), RT, 30 s; 83% (*Z*:*E* = 94:6); d) HF pyridine complex (11.2 equiv), THF, 0°C , 3 h; addition of silica gel powder (for flash chromatography) under continued stirring at 0°C , 15 min; 80% (*Z*:*E* = 96:4); e) Dess–Martin periodinane (1.1 equiv), CH₂Cl₂, RT, 5 min; 90% as a 95:5 mixture, recrystallized from EtOAc/pentane at -78°C as a 98:2 *Z*:*E* mixture; 82%.

anhydride in the presence of pyridine. We assume that the tris(triflate) **8** formed as a short-lived intermediate. It must have suffered two spontaneous β -eliminations. In all likelihood the first elimination gave rise to the endocyclic C=C bond of a butenolide triflate **10**^[11] whereas the second elimination introduced the crucial stereogenic semicyclic C=C bond, thus furnishing the alkylidenebutenolide triflate (*Z*)-**9**.^[12] This compound was isolated in 85% yield and with a *Z*:*E* ratio of >99:1 (after flash chromatography on silica gel^[13]).

At this point, two subgoals had been reached: the γ -carbon of butenolide (*Z*)-**9** was incorporated into a correctly and homogeneously configured C=C bond and the α -carbon was poised for a desoxygenation. The latter was realized through a transition metal complex catalyzed hydrogenolysis of the C–OTf bond with Bu₃SnH (Scheme 3). Using NiCl₂(PPh₃)₂ for this purpose for the first time, the reduction of (*Z*)-**9** went to completion at room temperature within only 30 s and provided 83% (*Z*)-**11**. The nickel catalyst was vastly superior to [PdCl₂(PPh₃)₂], [Pd(PPh₃)₄]^[14] or [Pd₂(dba)₃·CHCl₃], each of which required 100 times longer for hydrogenolysis (60 min) and still rendered only half the yield ($\leq 43\%$). The only drawback is that we could not entirely suppress an isomerization of the semicyclic double bond: (*Z*)-**11** showed an isomer ratio of *Z*:*E* = 94:6 (determined, as are all other isomer ratios of this study, from ¹H NMR integrals). The

ensuing steps were a desilylation with the HF pyridine complex^[15] to 80% of alcohol (*Z*)-**12**, which possessed a 96:4 *Z*:*E* composition, and a Dess–Martin oxidation.^[16] These provided 90% of aldehyde (*Z*)-**13** as a *Z*:*E* 95:5 mixture or, after recrystallization, 82% of almost isomerically pure material (*Z*:*E* = 98:2) (Scheme 3).

The presently achieved degree of configurational control of the semicyclic C=C bond of our synthetic intermediates (*Z*)-**9**, (*Z*)-**11**, (*Z*)-**12**, and (*Z*)-**13** of Scheme 3 surpasses our initial results considerably. Indeed, an undesired isomerization of this C=C bond threatened every step of the described sequence. In order to be sure that we dealt with *Z*-configured semicyclic C=C bonds throughout Scheme 3 we prepared all *E* isomers by the conceptually identical series of transformations depicted in Scheme 4 starting from *D*-mannono-1,4-lactone (*iso*-**6**). After monosilylation^[10] (\rightarrow **7**) the tandem



Scheme 4. a) *t*BuMe₂SiCl (1.0 equiv), imidazole (2.0 equiv), DMF, -30°C , 1 h; \rightarrow RT, 2 h; 62%; b) pyridine (5.0 equiv), Tf₂O (3.3 equiv), CH₂Cl₂, -78°C ; $\rightarrow 0^{\circ}\text{C}$, 120 min; 60% (*E*:*Z* > 99:1); c) LiCl (3.0 equiv), NiCl₂(PPh₃)₂ (2 mol %), THF, RT, 15 s; Bu₃SnH (1.1 equiv), RT, 30 s; 79% (*E*:*Z* = 83:17); d) HF pyridine complex (11.2 equiv), THF, 0°C , 3 h; addition of silica gel powder (for flash chromatography) under continued stirring at 0°C , 15 min; 76% (*E*:*Z* = 81:19); e) Dess–Martin periodinane (1.1 equiv), CH₂Cl₂, RT, 10 min; 81% (*E*:*Z* = 79:21).

triflation/ β -elimination reaction with triflic anhydride and pyridine provided the butenolide triflate (*E*)-**9** in 60% yield as a single isomer (*E*:*Z* > 99:1). This transformation constitutes one of our first realizations^[5] of the Scheme 2 approach to γ -alkylidenebutenolides (*E*)-**5** from γ -(α -hydroxyalkyl)butenolides *iso*-**4**.^[12] The [NiCl₂(PPh₃)₂]-catalyzed hydrogenolysis of triflate (*E*)-**9** with Bu₃SnH delivered compound (*E*)-**11** in 82% yield. However, we observed a competing isomerization of the semicyclic double bond lowering the *E*:*Z* ratio to 83:17. Desilylation of ether (*E*)-**11** by HF/pyridine^[15] gave 76% of the alcohol (*E*)-**12** (*E*:*Z* = 81:19). It was oxidized (81% yield) with Dess–Martin periodinane^[16] giving aldehyde (*E*)-**13** as a 79:21 *E*:*Z* mixture.

Having compounds **9** and **11–13** now as pairs of isomers in our hands, it was evident that each compound originating from the synthesis of Scheme 3 belonged to one configurational series and each compound emerging from a reaction of Scheme 4 to the *opposite* configurational series. This followed


from the groupwise similarities of the 300 MHz ¹H NMR shifts of the protons 1'-H and 4-H, respectively (Table 1). In *Z* vs. *E* isomers, these resonances were shifted upfield by about 0.5 ppm.^[17]

Table 1. ¹H NMR shifts (at 300 MHz in CDCl₃) distinguishing between *Z*- and *E*-configured γ -alkylidenebutenolides.

	R ¹	R ²	$\delta_{Z\text{-isomer}}$		$\delta_{E\text{-isomer}}$		$\delta_Z - \delta_E$	
			1'-H	4-H	1'-H	4-H	1'-H	4-H
9	<i>t</i> BuMe ₂ SiO-CH ₂	OTf	5.64	7.26	6.02	7.91	-0.38	-0.65
11	<i>t</i> BuMe ₂ SiO-CH ₂	H	5.41	7.36	5.83	7.85	-0.42	-0.49
12	HO-CH ₂	H	5.48	7.39	5.91	7.83	-0.43	-0.44
13	(O=)CH	H	5.63	7.59	6.18	8.13	-0.55	-0.54
1 (synthetic)	-	-	5.90	7.38	-	-	-	-
1 (natural) ^[4]	-	-	5.88	7.35	-	-	-	-

The highly unsaturated side-chain of dihydroxerulins (**1**) was prepared as shown in Scheme 5. Two 1,4-eliminations of HCl from the dichlorobutynes **14** gave the butadiyne dianion.^[18] Propylation of one of its termini^[18] and iodination of the other provided the iododiynes **17**.^[19] It was Stille-cross-coupled^[20] with the stannane **18** obtained from the pentenynol **15**^[21] and Bu₃SnH in one step.^[22] The resulting alcohol **19** was transformed via bromide **20**^[23] into the triphenylphosphonium salt **21**.^[24] The Wittig reaction between the ylid derived therefrom and the aldehyde (*Z*)-**13** brought the first synthesis of dihydroxerulins (**1**) to an end (Scheme 5). The target compound was initially obtained in a mixture with at least two isomers (55% total yield). Careful purification by repetitive passages through silica-gel-filled flash chromatography columns^[13] led to 30% of pure dihydroxerulins (**1**). Our synthesis encompasses 2 \times 5 consecutive steps in the two linear sequences which converge in the last, single, eleventh step. Our synthetic specimen of dihydroxerulins (**1**) was identical with the natural product,^[4] as evidenced by coinciding 500 MHz ¹H NMR shift values and coupling constants (in CDCl₃; Table 2).

What we felt remained to be proved from first NMR principles were the configurations of the stereogenic C⁴=C⁵, C⁶=C⁷, C⁸=C⁹, and C¹⁰=C¹¹ bonds of dihydroxerulins. Clearly, the route by which we obtained **1** already implies that the C⁴=C⁵, C⁸=C⁹, and C¹⁰=C¹¹ bonds of **1** possess the same configuration as the corresponding double bonds in the precursor aldehyde (*Z*)-**13** and phosphonium salt **21**. Independently, the *Z* configuration of the C⁴=C⁵ bond follows unequivocally from the ¹H NMR shift criterion established in entries 1–4 of Table 1 (compare with entries 5, 6). The C⁶=C⁷ and C¹⁰=C¹¹ bonds of **1** are clearly *trans* configured because of the magnitude of the vicinal coupling constants *J*_{6,7} (14.3 Hz) and *J*_{10,11} (15.5 Hz). However, we could not tell right away the configuration of the C⁸=C⁹ bond, since under the Steglich/Anke^[4] measuring conditions (500 MHz, CDCl₃) the 8-¹H/9-¹H NMR subspectrum of **1** is higher-order. Because signal spreading in the 8-¹H/9-¹H range was slightly larger in C₆D₆



Scheme 5. a) NaNH₂ (3.0 equiv), PrBr (1.1 equiv), NH₃/DMSO (6:1), –33 °C, 4 h; used crude (ref. [18] 58–62%); b) CuCN (1.1 equiv), BuLi (2.2 equiv), THF, –78 °C → RT, 30 min; → –78 °C, Bu₃SnH (1.1 equiv), then **15**, –78 °C, 2.5 h; 78% (ref. [22] 67%); c) I₂ (1.0 equiv), morpholine (3.0 equiv), THF, 45 °C, 10 h; 43% over the two steps; d) LiCl (3.0 equiv), PdCl₂(PPh₃)₂ (2 mol%), THF, RT, 5 h; 81%; e) NaBr (1.5 equiv), BF₃·OEt₂ (1.5 equiv), MeCN, RT, 6 h; 61%; f) PPh₃ (1.0 equiv), MeCN, RT, 12 h; 99%; g) *n*BuLi (1.0 equiv), THF, –83 °C, 3 min; (*Z*)-**13** (1.0 equiv), –83 °C, 6 h; → RT, 2 h; after repeated chromatography 30% **1** and 25% mixtures of other isomers.

Table 2. Comparison of ¹H NMR data at 500 MHz in CDCl₃ between synthetic and natural dihydroxerulin (**1**);^[4] chemical shifts in ppm, coupling constants in Hz.

proton	2	3	5	6	7–9	10	11	16	17	18
chemical shift										
natural 1 ^[4]	6.17	7.35	5.88	6.80	6.37–6.54	6.74	5.69	2.32	1.57	0.99
synthetic 1	6.19	7.38	5.90	6.82	6.39–6.56	6.77	5.72	2.35	1.59	1.01
couplings										
natural 1 ^[4]	³ J _{2,3}	⁵ J _{2,5}	³ J _{5,6}	³ J _{6,7}	³ J _{9,10}	³ J _{10,11}	⁷ J _{11,16}	³ J _{16,17}	³ J _{17,18}	
synthetic 1	5.5	0.5	11.8	14.5	10.5	15.5	1.2	7.0	7.5	
	5.4	–	11.9	14.3	10.5	15.5	1.0	7.1	7.3	

than in CDCl₃ we used the former for recording a 800 MHz 8-¹H/9-¹H NMR subspectrum of **1** as our ultimate means (Figure 1, top half). We then calculated (trial and error method) this subspectrum from the values δ_{7H} = 5.9725,




Figure 1. Experimental (top) and calculated (bottom) 8-¹H/9-¹H subspectrum of dihydroxerulin (**1**) at 800 MHz in C₆D₆.

δ_{10H} = 6.5190, *J*_{7,8} = 10.3 Hz, and *J*_{9,10} = 10.4 Hz which were directly accessible from the first-order resonances of 7-H and 10-H. We varied δ_{8H} in 0.000125-ppm steps between 5.8381 ± 0.0025 ppm, δ_{9H} in 0.000125-ppm steps between 5.8606 ± 0.0025 ppm, and *J*_{8,9} first in 0.5-Hz steps between 10.0 and 14.0 Hz and then in 0.2-Hz steps between 14.0 and 16.0 Hz until the calculated (Figure 1, top half) and experimental 8-¹H/9-¹H subspectrum (Figure 1, top half) coincided. In this case, δ_{8H} = 5.84, δ_{9H} = 5.86, and *J*_{8,9} = 14.8 Hz. The last value proves that the C⁸=C⁹ bond of dihydroxerulin (**1**) is *trans*-configured.

We are currently trying to expand the scope of our γ-(α-hydroxyalkyl)butenolide **4** → γ-alkylidenebutenolide **5** strategy to obtain xerulin (**2**) and xerulinic acid (**3**) by variations of our approach to dihydroxerulin (**1**) presented here.

Experimental Section

General methods: All reactions were performed in oven-dried (110 °C) glassware under N₂. Reactions with light-sensitive compounds were performed in brown glassware or in ordinary glassware wrapped by aluminum foil. THF was freshly distilled from K, CH₂Cl₂ and pyridine from CaH₂, MeCN from P₂O₁₀. Products were purified by flash chromatography^[13] on Merck silica gel 60 (eluents given in brackets; volume of each collected fraction (mL)/column diameter (cm): 1.3/1.0, 4/1.5, 8/2.0, 14/2.5, 20/3.0, 30/4, 50/5, 80/6, 125/7.5; which fractions contained the isolated product is indicated in each description as product in fractions xx-yy). Yields refer to analytically pure samples. Isomer ratios were derived from suitable ¹H NMR integrals. ¹H [CHCl₃ (δ = 7.26) as internal standard in CDCl₃ or C₆HD₅ (δ = 7.16) as internal standard in C₆D₆] and ¹³C NMR [C₆D₆ (δ = 128.00) as internal standard in C₆D₆]: Bruker AMX300 and Varian VXR 500S; integrals in accord with assignments; coupling constants in Hz. The assignments of ¹H and ¹³C NMR resonances refer to the IUPAC nomenclature and primed numbers belong to the side-chain, except for dihydroxerulin which was numbered as shown in Table 2. Combustion analyses: M. Beller and F. Hambloch, Institute of Organic Chemistry, University of Göttingen; MS: Dr. G. Remberg, Institute of Organic Chemistry, University of Göttingen; IR spectra: Perkin–Elmer 1600 Series FT-IR; UV spectra: Perkin–Elmer Lambda 2; melting points were measured on a Dr. Tottoli apparatus (Büchi) and are uncorrected.

Dihydroxerulin (1): *n*BuLi (2.5 M in hexane, 487 μL, 1.22 mmol, 1.0 equiv) was added to phosphonium salt **21** in THF (20 mL) at –83 °C. The

aldehyde (**Z**)-**13** (151 mg, 1.22 mmol) precooled at -83°C in THF (5 mL) was added to this solution after 3 min. The reaction was allowed to proceed at -83°C for 6 h and at room temp for 2 h. The solvent was removed in vacuo. The crude product was purified by flash chromatography (5 cm, fractions 1–9 petroleum ether:*t*BuOMe: CH_2Cl_2 10:1:1, fractions 10–19 petroleum ether:*t*BuOMe: CH_2Cl_2 5:1:1, product in fractions 7–19) yielded the title compound as a mixture of isomers (177 mg, 55%). Dihydroxerulins (**1**) could be separated from it by repeated flash chromatographies (3 cm, fractions 1–29 petroleum ether:*t*BuOMe: CH_2Cl_2 6:1:0.2, fractions 30–49 petroleum ether:*t*BuOMe: CH_2Cl_2 4:1:0.2, fractions 50–84 petroleum ether:*t*BuOMe: CH_2Cl_2 3:1:0.2, product in fractions 52–84). The pure title compound (96 mg, 30%) was isolated as an orange solid [m.p. $132\text{--}135^{\circ}\text{C}$ (decomp), ref. [4] $143\text{--}154^{\circ}\text{C}$ for a mixture with xerulins]. ^1H NMR (500 MHz): $\delta = 1.01$ (t, $J_{18,17} = 7.3$, 18-H₃), 1.59 (tq, $J_{17,18} = J_{17,16} = 7.2$, 17-H₂), 2.35 (td, $J_{16,17} = 7.0$, $^3J_{16,11} = 1.0$, 16-H₂), 5.72 (d, $J_{11,10} = 15.4$, 11-H), 5.90 (d, $J_{5,6} = 11.9$, 5-H), 6.19 (d, $J_{2,3} = 5.5$, 2-H), 6.39–6.56 (m, 7-H, 8-H, 9-H), 6.77 (dd, $J_{10,11} = 15.5$, $J_{10,9} = 10.5$, 10-H), 6.82 (dd, $J_{6,7} = 14.3$, $J_{6,5} = 11.8$, 6-H), 7.38 (d, $J_{3,2} = 5.3$, 3-H); ^1H NMR (800 MHz, C_6D_6 , C_6HD_5 as internal standard): $\delta = 0.73$ (t, $J_{18,17} = 7.4$, 18-H₃), 1.22 (qt, $J_{17,18} = J_{17,16} = 7.2$, 17-H₂), 1.91 (dt, $J_{16,17} = 7.0$, $^3J_{16,11} = 0.8$, 16-H₂), 5.08 (d, $J_{5,6} = 11.7$, 5-H), 5.45 (d, $J_{11,10} = 15.5$, 11-H), 5.48 (d, $J_{2,3} = 5.3$, 2-H), 5.78–5.88 (m, 8-H, 9-H)*, 5.97 (dd, $J_{6,7} = 14.8$, $J_{7,8} = 10.3$, 7-H), 6.23 (d, $J_{3,2} = 5.3$, 3-H), 6.52 (dd, $J_{10,11} = 15.4$, $J_{10,9} = 10.4$, 10-H), 6.57 (dd, $J_{6,7} = 15.1$, $J_{6,5} = 11.7$, 6-H); (* a computer analysis was done because these signals were higher-order; cf. body of the text). A $^3J_{\text{H},\text{H}}$ correlation spectrum (500 MHz, C_6D_6) shows cross-peaks between the following resonances: 2-H \leftrightarrow 3-H; 5-H \leftrightarrow 6-H; 6-H \leftrightarrow 7-H; 7-H \leftrightarrow 8-H/9-H; 8-H/9-H \leftrightarrow 7-H/10-H; 10-H \leftrightarrow 8-H/9-H; 10-H \leftrightarrow 11-H; 16-H₂ \leftrightarrow 17-H₂; 17-H₂ \leftrightarrow 18-H₃. A $^nJ_{\text{H},\text{H}}$ correlation spectrum (500 MHz, C_6D_6) shows cross-peaks between the following resonances: 2-H \leftrightarrow 3-H, 5-H; 3-H \leftrightarrow 2-H, 5-H; 5-H \leftrightarrow 2-H, 3-H, 6-H, 7-H; 6-H \leftrightarrow 5-H, 7-H; 7-H \leftrightarrow 5-H, 6-H, 8-H/9-H; 8-H/9-H \leftrightarrow 7-H, 10-H; 10-H \leftrightarrow 5-H, 8-H/9-H; 11-H \leftrightarrow 16-H₂; 16-H₂ \leftrightarrow 11-H, 17-H₂; 17-H₂ \leftrightarrow 16-H₂, 18-H₃; 18-H₃ \leftrightarrow 17-H₂; ^{13}C NMR (125.7 MHz, C_6D_6 , C_6D_6 as internal standard): $\delta = 13.37$ (C-18), 21.68 (C-16), 21.91 (C-17), 66.74 and 80.80 (C-13, C-14), 75.64 (C-12), 87.58 (C-15), 112.20 (C-11), 113.64 (C-5), 118.81 (C-2), ≈ 128 (C-6)*, 134.78 and 135.70 (C-8, C-9), 137.35 (C-7), 141.83 (C-3), 144.19 (C-10), 149.79 (C-4), 168.49 (C-1) (* signal superimposed by C_6D_6 and therefore not unambiguously identifiable). A $^1J_{\text{H},^{13}\text{C}}$ correlation spectrum (500 MHz and 125.7 MHz, respectively, C_6D_6) shows cross-peaks between the following resonances: 2-H \leftrightarrow C-2; 3-H \leftrightarrow C-3; 5-H \leftrightarrow C-5; 6-H \leftrightarrow C-6; 7-H \leftrightarrow C-7; 8-H/9-H \leftrightarrow C-8, C-9; 10-H \leftrightarrow C-10; 11-H \leftrightarrow C-11; 16-H₂ \leftrightarrow C-16; 17-H₂ \leftrightarrow C-17; 18-H₃ \leftrightarrow C-18. A $^nJ_{\text{H},^{13}\text{C}}$ correlation spectrum (500 MHz and 125.7 MHz, respectively, C_6D_6) shows cross-peaks between the following resonances: 2-H \leftrightarrow C-1, C-3, C-4; 3-H \leftrightarrow C-1, C-2, C-4; 5-H \leftrightarrow C-3, C-4, C-7; 6-H \leftrightarrow C-4; 7-H \leftrightarrow C-9; 8-H/9-H \leftrightarrow C-7, C-10; 10-H \leftrightarrow C-8; 11-H \leftrightarrow C-9, C-10, C-12; 16-H₂ \leftrightarrow C-12, C-13/C-14, C-15; 17-H₂ \leftrightarrow C-15, C-16, C-18; 18-H₃ \leftrightarrow C-17; IR (CDCl₃): $\nu = 3155, 2965, 2930, 2255, 1775, 1750, 1530, 1465, 1380, 1335, 1105, 1065, 995, 910, 735, 650\text{ cm}^{-1}$; UV (MeOH): λ_{max} (lg ϵ) = 396 (5.61), 413 (5.64) nm; $\text{C}_{18}\text{H}_{16}\text{O}_2$ (264.3): calcd C 81.79, H 6.10; found C 81.98, H 6.08; $m/z = 264.1150 \pm 2\text{ mDa}$ (M^+) confirmed by HRMS (EI, 70 eV).

(–)-**L-6-(tert-Butyldimethylsilyl)-gulono-1,4-lactone (7)**: A solution of *tert*-butyldimethylsilyl chloride (1.05 g, 7.00 mmol, 0.95 equiv) in CH_2Cl_2 (5 mL) was added to a mixture of *L*-gulono-1,4-lactone (**6**; 1.31 g, 7.30 mmol) and imidazole (0.94 g, 13.9 mmol, 1.9 equiv) in DMF (15 mL) at -40°C over 2 h. The mixture was stirred at -30°C for 1 h and at RT for 2 h. It was poured into ice water (50 mL) and extracted with *t*BuOMe (3 \times 50 mL). The organic layers were dried over Na_2SO_4 . After removal of the solvent, flash chromatography (4 cm, fractions 1–5 petroleum ether:*t*BuOMe 1:1, fractions 6–12 *t*BuOMe, product in fractions 8–12) yielded the title compound (1.25 g, 58%) as a glassy solid. $[\alpha]_{\text{D}}^{20} = -29.6$ ($c = 0.96$ in acetone); ^1H NMR (300 MHz): $\delta = 0.12$ [s, Si(CH₃)₂], 0.91 (s, *t*Bu), 2.84 (d, $J_{5,5\text{-OH}} = 3.4$, 5-OH), 3.21 (d, $J_{2,2\text{-OH}} = 7.3$, 2-OH), AB signal ($\delta_{\text{A}} = 3.75$, $\delta_{\text{B}} = 3.84$, $J_{\text{AB}} = 10.5$, in addition split by $J_{\text{A},5} = 7.9$, $J_{\text{B},5} = 4.9$, 6-H₂), superimposed 3.71 (d, $J_{3,3\text{-OH}} = 2.2$, 3-OH), 4.15 (m_c, 5-H), 4.39 (dd, $J_{4,5} = 5.7$, $J_{4,3} = 3.0$, 4-H), 4.46 (dd, $J_{2,2\text{-OH}} = 7.0$, $J_{2,3} = 5.1$, 2-H), 4.54 (m_c, presumably hardly resolved ddd, $J_{3,2} \approx 5.0$, $J_{3,3\text{-OH}} \approx J_{3,4} \approx 2.5$, 3-H); IR (CHCl₃): $\nu = 3550, 2955, 2860, 1780, 1465, 1255, 1195, 1120, 840, 790, 765\text{ cm}^{-1}$; $\text{C}_{12}\text{H}_{24}\text{O}_6\text{Si}$ (292.4): calcd C 49.29, H 8.29; found C 49.29, H 8.40.

(–)-**D-6-O-(tert-Butyldimethylsilyl)-mannono-1,4-lactone (iso-7)** was prepared from *tert*-butyldimethylsilyl chloride (50 wt % in toluene, 9.00 mL, 3.91 g, 25.9 mmol, 1.0 equiv), *D*-mannono-1,4-lactone (*iso-6*; 4.614 g,

25.93 mmol), and imidazole (3.531 g, 51.86 mmol, 2.0 equiv) as a glassy solid (4.723 g, 62%) analogously as described for the preparation of compound **7**. $[\alpha]_{\text{D}}^{20} = -15.6$ ($c = 0.77$ in CHCl₃); ^1H NMR (300 MHz, contains 4 mol % = 1 wt % *t*BuOMe): $\delta = 0.10$ [2 \times s, Si(CH₃)₂], 0.91 (s, *t*Bu), 3.28 (br s, 3 \times OH), AB signal ($\delta_{\text{A}} = 3.80$, $\delta_{\text{B}} = 3.88$, $J_{\text{AB}} = 10.7$, in addition split by $J_{\text{A},5} = 3.7$, $J_{\text{B},5} = 3.6$, 6-H₂), 4.04 (ddd, $J_{5,4} = 8.7$, $J_{5,6\text{H(A)}} \approx J_{5,6\text{H(B)}} = 3.9$, 5-H), 4.32 (dd, $J_{4,5} = 8.7$, $J_{4,3} = 2.7$, 4-H), 4.51 (d, $J_{2,3} = 4.5$, 2-H), 4.64 (dd, $J_{3,2} = 4.7$, $J_{3,4} = 2.9$, 3-H); IR (CHCl₃): $\nu = 2975, 1790, 1465, 1365, 1230, 1210, 1075, 845, 780, 765, 750\text{ cm}^{-1}$; $\text{C}_{12}\text{H}_{24}\text{O}_6\text{Si}$ (292.4): calcd C 49.29, H 8.27; found C 49.41, H 8.07.

5-[(Z)-2-(tert-Butyldimethylsilyloxy)ethylidene]-3-(trifluoromethanesulfonyl)-2(5H)-furanone [(Z)-9]: Triflic anhydride (3.219 g, 1.42 mmol, 3.3 equiv) was added to a solution of triol **7** (1.000 g, 3.420 mmol) and pyridine (1.353 g, 17.10 mmol, 5.0 equiv) in CH_2Cl_2 (40 mL) at -78°C over 40 min. The mixture was allowed to warm to -20°C over 80 min and subsequently stirred between -20 and -10°C for 90 min. It was recooled to -78°C and poured without workup onto a flash chromatography column (5 cm, CH_2Cl_2 , product in fractions 6–9). The title compound (1.135 g, 85%) was eluted as a white solid (m.p. 45°C). Small signals of (*E*)-**9** at $\delta = 6.02$ (1'-H) and $\delta = 7.91$ (4-H) showed *Z*:*E* selectivity of $>99:1$. ^1H NMR (300 MHz): $\delta = 0.08$ [s, Si(CH₃)₂], 0.89 (s, *t*Bu), 4.54 (d, $J_{2,1'} = 6.4$, 2'-H₂), 5.64 (t, $J_{1,2'} = 6.4$, 1'-H), 7.26 (s, 4-H)* (* this signal was caused by (*Z*)-**9**, as proved by integration); IR (CDCl₃): $\nu = 2930, 2860, 1800, 1610, 1440, 1230, 1135, 1075, 1050, 900, 840, 760, 715, 650\text{ cm}^{-1}$. $\text{C}_{13}\text{H}_{19}\text{F}_3\text{O}_6\text{Si}$ (388.4): calcd C 40.20, H 4.93; found C 40.49, H 4.79.

5-[(E)-2-(tert-Butyldimethylsilyloxy)ethylidene]-3-(trifluoromethanesulfonyl)-2(5H)-furanone [(E)-9] was prepared from triflic anhydride (3.322 g, 11.78 mmol, 3.3 equiv), triol *iso-7* (1.032 g, 3.530 mmol), and pyridine (1.394 g, 17.65 mmol, 5.0 equiv) as a colorless liquid (816 mg, 60%) as described for the preparation of compound (*Z*)-**9**. Here, (*Z*)-**9** was not detectable by ^1H NMR. ^1H NMR (300 MHz): $\delta = 0.13$ [s, Si(CH₃)₂], 0.94 (s, *t*Bu), 4.56 (d, $J_{2,1'} = 4.5$, 2'-H₂), 6.02 (t, $J_{1,2'} = 4.7$, 1'-H), 7.91 (s, 4-H); IR (CDCl₃): $\nu = 2960, 2930, 2895, 2860, 1800, 1785, 1610, 1440, 1225, 1175, 1135, 1110, 1070\text{ cm}^{-1}$; $\text{C}_{13}\text{H}_{19}\text{F}_3\text{O}_6\text{Si}$ (388.4): calcd C 40.20, H 4.93; found C 40.31, H 4.93.

5-[(Z)-2-(tert-Butyldimethylsilyloxy)ethylidene]-2(5H)-furanone [(Z)-11]: A mixture of LiCl (460 mg, 10.8 mmol, 3.0 equiv) and NiCl₂(PPh₃)₂ (46 mg, 70 μmol , 2 mol %) was added to a solution of the triflate (*Z*)-**9** (1.400 g, 3.605 mmol) in THF (15 mL). After 15 s Bu₃SnH (1.158 g, 3.969 mmol, 1.1 equiv) was added dropwise while stirring in a water bath maintained at 25°C . The color of the reaction mixture changed from blue via green to brown. The reaction was finished after 30 s (TLC). The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (3 cm, fractions 1–9 petroleum ether:*t*BuOMe 10:1, fractions 10–30 petroleum ether:*t*BuOMe 5:1, product in fractions 17–30). The title compound (720 mg, 83%) was obtained as a colorless oil. It was contaminated with 6% of (*E*)-**11** [calculated from ^1H integrals of 4-H ($\delta_{\text{E-11}} = 7.85$), 1'-H ($\delta_{\text{E-11}} = 5.83$), and 2'-H ($\delta_{\text{E-11}} = 4.47$)]. ^1H NMR (300 MHz): $\delta = 0.09$ [s, Si(CH₃)₂], 0.90 (s, *t*Bu), 4.54 (d, $J_{2,1'} = 6.4$, 2'-H₂), 5.41 (t, $J_{1,2'} = 6.4$, 1'-H), 6.21 (d, $J_{3,4} = 5.2$, 3-H), 7.36 (d, $J_{4,3} = 5.3$, 4-H); IR (film): $\nu = 2930, 2855, 1780, 1465, 1255, 1205, 1105, 990, 930, 835, 780\text{ cm}^{-1}$. $\text{C}_{12}\text{H}_{20}\text{O}_3\text{Si}$ (240.4): calcd C 59.96, H 8.39; found C 59.86, H 8.46.

5-[(E)-2-(tert-Butyldimethylsilyloxy)ethylidene]-2(5H)-furanone [(E)-11] was prepared from LiCl (71 mg, 1.7 mmol, 3.0 equiv), NiCl₂(PPh₃)₂ (72 mg, 11 μmol , 2 mol %), triflate (*Z*)-**9** (217 mg, 0.559 mmol), and Bu₃SnH (180 mg, 0.615 mmol, 1.1 equiv) as a colorless oil (106 mg, 79%) analogously as described for the preparation of compound (*Z*)-**11**. It was contaminated with 17% of (*Z*)-**11** [calculated from ^1H integrals of 4-H ($\delta_{\text{Z-11}} = 7.36$), 1'-H ($\delta_{\text{Z-11}} = 5.41$), and 2'-H ($\delta_{\text{Z-11}} = 4.54$)]. ^1H NMR (300 MHz, contains 2 wt % *t*BuOMe): $\delta = 0.11$ [s, Si(CH₃)₂], 0.92 (s, *t*Bu), 4.47 (d, $J_{2,1'} = 6.1$, 2'-H₂), 5.83 (incompletely resolved tdd, $J_{1,2'} = 5.7$, $^5J_{1,3} = 1.9$, $^4J_{1,4} = 1.0$, 1'-H), 6.22 (ddm, $J_{3,4} = 5.6$, $^5J_{3,1} = 1.9$, 3-H, superimposed by the corresponding signal of the *Z* isomer), 7.85 (incompletely resolved dd, $J_{4,3} = 5.6$, $^4J_{4,1} = 0.7$, 4-H); IR (CDCl₃): $\nu = 2930, 2855, 1780, 1675, 1460, 1390, 1255, 1100, 1070, 990, 835, 780\text{ cm}^{-1}$; $\text{C}_{12}\text{H}_{20}\text{O}_3\text{Si}$ (240.4): calcd C 59.96, H 8.39; found C 59.99, H 8.03.

5-[(Z)-2-Hydroxyethylidene]-2(5H)-furanone [(Z)-12]: HF pyridine complex (1.50 mL, 1.36 g, 36.1 mmol, 11.2 equiv) was added to a solution of the silylether (*Z*)-**11** [contaminated with 6% of (*E*)-**11**; 770 mg, 3.21 mmol] in THF (20 mL) at 0°C . After stirring at 0°C for 3 h silica gel for flash

chromatography (300 mg) was added. The mixture was filtered through a pad of Celite® after stirring at 0 °C for 15 min. The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (3 cm, fractions 1–9 petroleum ether:*t*BuOMe 1:1, fractions 10–3 *t*BuOMe, product in fractions 15–23). The title compound (325 mg, 80%) was obtained as colorless oil. It was contaminated with 4% of (*E*)-**12** [calculated from ¹H integrals of 4-H ($\delta_{E-12} = 7.83$), and 1'-H ($\delta_{E-12} = 5.91$)]. ¹H NMR (300 MHz): $\delta = 1.74$ (t, $J_{2,OH} = 5.9$, OH), 4.54 (brt, $J_{2,1'} \approx J_{2,OH} = 6.4$, 2'-H₂), 5.48 (t, $J_{1,2'} = 6.5$, 1'-H), 6.25 (d, $J_{3,4} = 5.7$, 3-H), 7.39 (d, $J_{4,3} = 5.2$, 4-H); IR (CDCl₃): $\nu = 3610, 3150, 2975, 1775, 1750, 1675, 1560, 1465, 1385, 1315, 1215, 1115, 1060, 965, 920, 900, 880, 765, 705$ cm⁻¹; C₆H₆O₃ (126.1): calcd C 57.14, H 4.80; found C 57.08, H 4.75.

5-[(*E*)-2-Hydroxyethylidene]-2(5*H*)-furanone [(*E*)-12**]** was prepared from HF pyridine complex (0.110 mL, 100 mg, 2.91 mmol, 14.0 equiv) and silylether (*E*)-**11** [contaminated with 17% of (*Z*)-**11**, 50 mg, 0.20 mmol] as a colorless oil (20 mg, 76%) as described for the preparation of compound (*Z*)-**12**. It was contaminated with 19% of (*E*)-**12** [calculated from ¹H integrals of 4-H ($\delta_{Z-12} = 7.39$), and 1'-H ($\delta_{Z-12} = 5.48$)]. ¹H NMR (300 MHz, contains 8 wt % *t*BuOMe): $\delta = 2.00$ (brs, OH), 4.47 (d, $J_{2,1'} = 6.8$, 2'-H₂), 5.91 (td, $J_{1,2'} = 6.9$, $J_{1,3} = 1.6$, 1'-H), 6.27 {dd, $J_{3,4} = 5.7$, $J_{3,1'} = 1.5$, 3-H [partly superimposed by the corresponding signal of (*Z*)-**12**]}, 7.83 (d, $J_{4,3} = 5.7$, 4-H); IR (CDCl₃): $\tilde{\nu} = 3335, 3135, 3100, 2930, 1745, 1670, 1555, 1420, 1305, 1195, 1120, 1065, 1010, 975, 910, 820$ cm⁻¹; C₆H₆O₃ (126.1): calcd C 57.14, H 4.80; found C 57.63, H 5.51.

5-[(*Z*)-Formylmethylene]-2(5*H*)-furanone [(*Z*)-13**]**: Dess–Martin periodinane (1.082 g, 2.540 mmol, 1.1 equiv) was added to a solution of the alcohol (*Z*)-**12** [contaminated with 4% of (*E*)-**12**, 291 mg, 2.31 mmol] in CH₂Cl₂ (3 mL, not dry). The solution was diluted with *t*BuOMe (30 mL) and filtered through a pad of Celite after 5 min. The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (3 cm, fractions 1–7 petroleum ether:*t*BuOMe 1:1, fractions 8–20 *t*BuOMe, product in fractions 13–20). The title compound (258 mg, 90%) was obtained as a yellow solid. Recrystallization from EtOAc/pentane at –78 °C yielded (*Z*)-**13** (235 mg, 82%, m.p. 58 °C) as yellow crystals contaminated with 2% of (*E*)-**13** [calculated from ¹H integrals of 2'H ($\delta_{E-13} = 10.01$), 4-H ($\delta_{E-13} = 8.13$), 3-H ($\delta_{E-13} = 6.66$), and 1'H ($\delta_{E-13} = 6.18$)]. ¹H NMR (300 MHz): $\delta = 5.63$ (d, $J_{1,2'} = 7.9$, 1'-H), 6.51 (dd, $J_{3,4} = 5.7$, $J_{3,1'} = 0.8$, 3-H), 7.59 (d, $J_{4,3} = 5.3$, 4-H), 10.24 (d, $J_{2,1'} = 7.9$, 2'-H); IR (CDCl₃): $\nu = 2925, 2855, 1795, 1675, 1645, 1620, 1560, 1190, 1100, 1080$ cm⁻¹; C₆H₄O₃ (124.1): calcd C 58.07, H 3.25; found C 58.20, H 3.46.

5-[(*E*)-Formylmethylene]-2(5*H*)-furanone [(*E*)-13**]** was prepared from Dess–Martin periodinane (751 mg, 1.76 mmol, 1.1 equiv) and alcohol (*E*)-**12** [contaminated with 19% of (*Z*)-**12**, 202 mg, 1.60 mmol] as a yellow oil (162 mg, 81%) analogously as described for the preparation of compound (*Z*)-**13**. It was contaminated with 21% of (*Z*)-**13** [calculated from ¹H integrals of 2'H ($\delta_{Z-13} = 10.24$), 4-H ($\delta_{Z-13} = 7.59$), 3-H ($\delta_{Z-13} = 6.51$), and 1'-H ($\delta_{Z-13} = 5.63$)]. ¹H NMR (300 MHz): $\delta = 6.18$ (hardly resolved dd, $J_{1,2'} = 6.3$, $J_{1,3} = 0.9$, 1'-H), 6.66 (dd, $J_{3,4} = 5.6$, $J_{3,1'} = 1.9$, 3-H), 8.13 (d, $J_{4,3} = 5.7$, 4-H), 10.01 (d, $J_{2,1'} = 6.4$, 2'-H); IR (CDCl₃): $\nu = 3115, 2855, 2765, 2260, 1800, 1680, 1560, 1405, 1360, 1305, 1190, 1100, 955, 900, 855, 745$ cm⁻¹; C₆H₄O₃ (124.1): calcd C 58.07, H 3.25; found C 57.84, H 3.47.

1,3-Heptadiyne (16): Na (10.35 g, 450 mmol, 3.0 equiv) and a catalytic amount of Fe(NO₃)₃·9H₂O (100 mg) were dissolved in liquid NH₃ (300 mL). After stirring at –33 °C for 60 min the dichloride **14** was added at –55 °C over 60 min. Subsequently, propyl bromide (272 mL, 299 mmol, 1.1 equiv) was added at –33 °C over 15 min and DMSO (50 mL) was added at once. The reaction was allowed to proceed at –33 °C for 4 h; then the mixture was poured into ice-water (1000 mL), filtered, and extracted with pentane (3 × 300 mL). The organic layers were dried over MgSO₄ and concentrated to 50 mL by distilling off the solvent through a Vigreux column. Distillation yielded **16** as a colorless liquid (26%, b.p. (64 mbar) 64 °C, ref. [18] 58–62%). Higher overall yields resulted when we worked with a concentrated solution of **16** in pentane. ¹H NMR (300 MHz): $\delta = 1.00$ (t, $J_{7,6} = 7.4$, 7-H₃), 1.57 (tq, $J_{6,5} = J_{6,7} = 7.2$, 6-H₂), 1.96 (hardly resolved d, $J_{1,5} = 1.2$, 1-H), 2.23 (td, $J_{5,6} = 7.0$, $J_{5,1} = 1.0$, 5-H₂).

1-Iodo-1,3-heptadiyne (17): Morpholine (38.55 mL, 38.55 g, 442.5 mmol, 3.0 equiv) was added to a solution of I₂ (38.1 g, 150.1 mmol, 1.0 equiv) in THF (150 mL) at 45 °C. The solution of 1,3-heptadiyne (**16**) in pentane obtained as described above was added to the reaction mixture at 45 °C after 30 min. The reaction was allowed to proceed for 10 h. The mixture

was washed with a satd. aqueous solution of Na₂S₂O₃ (2 × 200 mL). The aqueous layers were re-extracted with *t*BuOMe (3 × 150 mL). The combined organic layers were dried over MgSO₄. The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (3 cm, petroleum ether, product in fractions 4–10). The title compound (13.98 g, 43% over the two steps) was obtained as a yellow oil. ¹H NMR (300 MHz): $\delta = 0.99$ (t, $J_{7,6} = 7.4$, 7-H₃), 1.56 (qt, $J_{6,7} = J_{6,5} = 7.2$, 6-H₂), 2.28 (t, $J_{5,6} = 7.2$, 5-H₂); IR (film): $\nu = 2985, 2930, 2230, 1725, 1460, 1035$ cm⁻¹; C₇H₈I (218.0): calcd C 38.56, H 3.24; found C 38.29, H 3.37.

5-(Tributylstannyl)-2,4-dien-1-ol (18): *n*BuLi (1.2 M in hexane, 93.0 mL, 110 mmol, 2.2 equiv) was added to a suspension of CuCN (4.92 g, 55.0 mmol, 1.1 equiv) in THF (150 mL) at –78 °C. The clear solution was allowed to warm to RT over 30 min and subsequently cooled to –78 °C. Bu₃SnH (32.12 g, 110 mmol, 2.2 equiv) was added over 10 min. After 15 min the alkyne **15** (4.10 g, 50.0 mmol) was added over 5 min. The reaction was allowed to proceed at –78 °C for 2.5 h, then the mixture was poured into a buffer of conc. aqueous NH₃ (20 mL) and satd. aqueous NH₄Cl (180 mL) and extracted with *t*BuOMe (3 × 150 mL). The organic layers were dried over Na₂SO₄. The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (5 cm, petroleum ether:*t*BuOMe 10:1+1% NEt₃, product in fractions 10–20). The title compound (14.520 g, 78%) was obtained as a colorless liquid. ¹H NMR (300 MHz): $\delta = 0.87$ – 0.94 (m, 3 × CH₂-CH₂-CH₂-CH₃), superimposed by 0.89 (t, $J = 7.4$, 3 × CH₂-CH₂-CH₂-CH₃), 1.31 (tq, both of $J = 7.2$, 3 × CH₂-CH₂-CH₂-CH₃), 1.44–ca. 1.58 (m, CH₂-CH₂-CH₂-CH₃, OH), 4.20 (brd, $J_{1,2} = 5.6$, 1-H₂), 5.80 (dt, $J_{2,3} = 15.6$, $J_{2,1} = 5.9$, 2-H), 6.24 (ddm_c, $J_{3,2} \approx 15$, $J_{3,4} \approx 10$, 3-H), superimposed by 6.26 (d, $J_{5,4} = 18.8$, 5-H), 6.54 (dd with extra peaks caused by transition to higher-order spectrum, $J_{4,5} = 18.9$, $J_{4,3} = 9.7$, 4-H); C₁₇H₃₄OSn (373.2): calcd C 54.72, H 9.18; C 54.97, H 9.14.

trans,trans-2,4-Dodecadiene-6,8-diyne-1-ol (19): A mixture of LiCl (1.938 g, 45.81 mmol, 3.0 equiv) and PdCl₂(PPh₃)₂ (215 mg, 0.304 mmol, 0.02 equiv) was added to a solution of the iodide **17** (3.300 g, 15.17 mmol) in THF (20 mL). The stannane **18** (6.790 g, 18.20 mmol, 1.2 equiv) was added after 2 min. The reaction mixture was washed with saturated aqueous Na₂S₂O₃ (3 × 100 mL) after 5 h. The aqueous phases were re-extracted with *t*BuOMe (3 × 80 mL). The combined organic layers were dried over MgSO₄. The crude product obtained after removal of the solvent in vacuo was purified by flash chromatography (4 cm, petroleum ether (300 mL), fractions 1–9 petroleum ether:*t*BuOMe 10:1, fractions 10–14 petroleum ether:*t*BuOMe 5:1, fractions 15–19 petroleum ether:*t*BuOMe 2:1, fractions 20–48 petroleum ether:*t*BuOMe 1:1, product in fractions 32–48). The title compound (2.130 g, 81%) was obtained as a yellow solid (m.p. 68 °C). ¹H NMR (300 MHz): $\delta = 1.00$ (t, $J_{12,11} = 7.4$, 12-H₃), 1.39 (t, $J_{OH,1} = 5.9$, OH), 1.58 (qt, $J_{11,12} = J_{11,10} = 7.2$, 11-H₂), 2.32 (t, $J_{10,11} = 7.0$, 10-H₂), 4.24 (br dd, $J_{1,OH} = J_{1,2} = 5.5$, 1-H₂), 5.62 (br d, $J_{5,4} = 15.5$, 5-H), 5.96 (dt, $J_{2,3} = 15.4$, $J_{2,1} = 5.5$, 2-H), 6.32 (ddm_c, $J_{3,2} \approx 15.0$, $J_{3,4} \approx 11.0$, 3-H*), 6.68 (dd, $J_{4,5} = 15.4$, $J_{4,3} = 10.9$, 4-H*) (* the distinction of 3-H vs 4-H is based on an increment calculation^[25] which predicts $\delta_{3H} = 6.24$ and $\delta_{4H} = 6.87$); IR (KBr): $\nu = 3125, 1620, 1400, 1090, 985$ cm⁻¹; UV (MeOH): λ_{max} (lg ϵ) = 226 (5.40), 235 (5.56), 292 (5.48), 310 (5.41) nm; C₁₂H₁₃O (174.2): calcd C 82.72, H 8.10; found C 82.65, H 8.31.

trans,trans-1-Bromo-2,4-dodecadiene-6,8-diyne (20): BF₃·OEt₂ (264 mg, 2.59 mmol, 1.5 equiv) was added to a suspension of alcohol **19** (300 mg, 1.72 mmol) and NaBr (266 mg, 2.59 mmol, 1.5 equiv) in MeCN (15 mL). After 6 h the solution was filtered through a column for flash chromatography (5 cm, filled 4 cm by height, petroleum ether:*t*BuOMe 10:1, product in fractions 2–6). The title compound (248 mg, 61%) was obtained as a yellow oil. ¹H NMR (300 MHz; contains 2 wt % CH₂Cl₂): $\delta = 1.00$ (t, $J_{12,11} = 7.4$, 12-H₃), 1.58 (tq, $J_{11,10} = J_{11,12} = 7.2$, 11-H₂), 2.33 (t, $J_{10,11} = 7.0$, 10-H₂), 4.02 (d, $J_{1,2} = 7.9$, 1-H₂), 5.67 (br d, $J_{5,4} = 15.8$, 5-H), 5.99 (td, $J_{2,3} = 15.1$, $J_{2,1} = 7.6$, 2-H), 6.31 (dd, $J_{3,2} = 14.7$, $J_{3,4} = 11.0$, 3-H*), 6.66 (ddm_c, $J_{4,5} = 15.5$, $J_{4,3} = 11.0$, 4-H*) (* distinction of 3- vs. 4-H in analogy to compound **19**); C₁₂H₁₃Br (237.1): calcd C 60.78, H 5.53; found C 58.48, H 5.58. No better CH analysis could be obtained.

(trans,trans-2,4-Dodecadiene-6,8-diyne)triphenylphosphonium bromide (21): PPh₃ (282 mg, 1.07 mmol, 1.0 equiv) was added to a solution of the bromide **20** (253 mg, 1.07 mmol) in MeCN (10 mL). The solvent was removed in vacuo after 12 h. The title compound (530 mg, 99%) was obtained as red rubbery mass. ¹H NMR (300 MHz): $\delta = 0.98$ (t, $J_{12,11} = 7.4$, 12-H₃), 1.56 (qt, $J_{11,12} = J_{11,10} = 7.2$, 11-H₂), 2.30 (t, $J_{10,11} = 7.0$, 10-H₂), 4.96 (dd, $J_{1,P} = 16.2$, $J_{1,2} = 7.5$, 1-H₂), 5.55 (dd, $J_{5,4} = 15.5$, $J_{5,P} = 2.3$, 5-H),

superimposes the two high-field branches of 5.62 (dtd, $J_{2,3} = 14.3$, $J_{2,1} = {}^3J_{2,P} = 7.3$, 2-H), AB signal [$\delta_A = 6.49$, $\delta_B = 6.61$, $J_{AB} = 11.6$, in addition split by $J_{A,S} = 15.1$, ${}^5J_{A,P} = 0.8$ (only recognizable in two of the four main branches of this signal), $J_{B,2} = 14.4$, ${}^4J_{B,P} = 4.9$, A: 4-H, B: 3-H], 7.65–7.72 and 7.77–7.89 (2m, of 6 and 9H, respectively, ArH); IR (film): $\nu = 3055, 2960, 1635, 1435, 1110, 995, 745, 725, 690 \text{ cm}^{-1}$; $C_{30}H_{28}BrP$ (499.4) calcd C 72.15, H 5.65; found C 71.90, H 5.57.

Acknowledgments: We are grateful for a doctoral stipend for K.S. from the Fonds der Chemischen Industrie. In addition, we thank the Sonderforschungsbereich 416 of the Deutsche Forschungsgemeinschaft and the Acciones Integradas program of the Deutscher Akademischer Austauschdienst for financial support, and Witco GmbH and Wacker AG for donating chemicals. We would like to express our gratitude to Professor Christian Griesinger (Johann-Wolfgang-Goethe-Universität, Frankfurt am Main) and to Dipl.-Chem. Reinhard Machinek (Georg-August-Universität, Göttingen) for measuring high-field spectra of compound **1** and assisting in their analysis.

Received: December 17, 1997 [F942]

- [1] a) Reviews: Y. S. Rao, *Chem. Rev.* **1976**, *76*, 625–694; b) G. Pattenden, *Prog. Chem. Nat. Prod.* **1978**, *35*, 133–198; c) D. W. Knight, *Contemp. Org. Synth.* **1994**, *1*, 287–315.
- [2] a) For example bovidiol: G. Lardelli, G. Dijkstra, P. D. Harkes, J. Boldnight, *Recl. Trav. Chim. Pays-Bas* **1966**, *85*, 43–55; b) freelingyne: R. A. Massy-Westropp, G. D. Reynolds, T. M. Spotswood, *Tetrahedron Lett.* **1966**, 1939–1946; c) xylyerythrin: J. Gripenberg, J. Martikala, *Acta Chem. Scand.* **1969**, *23*, 2583–2588; d) eremolactone: A. J. Birch, G. S. R. S. Rao, J. P. Turnbull, *Tetrahedron Lett.* **1966**, 4749–4751; e) tetrenolin: G. G. Gallo, C. Coronelli, A. Vigevani, G. C. Lancini, *Tetrahedron* **1969**, *25*, 5677–5680; H. Pagani, G. Lancini, G. Tamoni, C. Coronelli, *J. Antibiot.* **1973**, *26*, 1–6; f) pyrrhoxanthin and peridin: J. E. Johansen, W. A. Svec, S. Liaaen-Jensen, F. T. Haxo, *Phytochemistry* **1974**, *13*, 2261–2271; g) lissoclinol: B. S. Davidson, C. M. Ireland, *J. Nat. Prod.* **1990**, *53*, 1036–1038.
- [3] a) For example protoanemonin: H. Baer, M. Holden, B. C. Seegal, *J. Biol. Chem.* **1946**, *162*, 65–68; b) maritricaria lactones: F. Bohlmann, H. Mönch, P. Blaszkiewicz, *Chem. Ber.* **1967**, *100*, 611–617 and references therein; c) cumulene-substituted butenolides: F. Bohlmann, H. Bornowski, C. Arndt, *ibid.* **1965**, *98*, 2236–2242; d) F. Bohlmann, C. Zdero, *Tetrahedron Lett.* **1970**, 2465–2466; e) a lactone from *Carlina vulgaris*: F. Bohlmann, K.-M. Rode, *Chem. Ber.* **1967**, *100*, 1507–1514; g) goniobutenolides A and B: X.-p. Fang, J. E. Anderson, C.-J. Chang, J. L. McLaughlin, *Tetrahedron* **1991**, *47*, 9751–9758; h) X.-p. Fang, J. E. Anderson, C.-J. Chang, P. E. Fanwick, J. L. McLaughlin, *J. Chem. Soc. Perkin Trans. 1* **1990**, 1655–1661; j) compounds **1–3**: ref. [4].
- [4] D. Kuhnt, T. Anke, H. Besl, M. Bross, R. Herrmann, U. Mocek, B. Steffan, W. Steglich, *J. Antibiot.* **1990**, *43*, 1413–1420.
- [5] A. Umland, Diplomarbeit, Universität Göttingen, **1996**; K. Siegel, Diplomarbeit, Universität Göttingen, **1997**; F. von der Ohe, Diplomarbeit, Universität Göttingen, **1997**.
- [6] a) F. Bohlmann, C. Zdero, *Chem. Ber.* **1966**, *99*, 1226–1228; b) J. B. Jones, J. M. Young, *J. Med. Chem.* **1968**, *11*, 1176 (cited from J. Font, R. M. Ortuño, F. Sánchez-Fernando, C. Segura, N. Terris, *Synth. Commun.* **1989**, *19*, 2977–2985); c) K. Yamada, Y. Togawa, T. Kato, Y. Hirata, *Tetrahedron* **1971**, *27*, 5445–5451; d) S. Tsuboi, H. Wada, S. Mimura, A. Takeda, *Chem. Lett.* **1987**, 937–938.
- [7] a) H. Itoh, *Noguchi Kenkyusho Jiho* **1984**, 15–18 (cited from *Chem. Abst.* **1986**, *104*, 168723c); b) M. Ito, Y. Hirata, Y. Shibata, K. Tsukida, *J. Chem. Soc. Perkin Trans. I* **1990**, 197–199; c) C. Di Nardo, L. O. Jeronic, R. M. Lederkremer, O. Varela, *J. Org. Chem.* **1996**, *61*, 4007–4013.
- [8] Syntheses of *E,Z* isomeric α,β -dimethoxy- γ -alkylidenebutenolides, which are considerably more configurationally stable than the methoxy-free γ -alkylidenebutenolides **5a–f**, by stereospecific anti-elimination of methanesulfonic acid from γ -[(α -mesyloxy)alkyl]butenolides were reported by M. A. Khan, H. Adams, *Synthesis* **1995**, 687–692.
- [9] All new compounds gave satisfactory ${}^1\text{H}$ NMR spectra (300 MHz, CDCl_3), IR spectra (film, CDCl_3 solution or in KBr), and, with the exception of (*E*)-**12** and **20**, correct combustion analyses.
- [10] For experimental details see an analogous reaction described by M. G. B. Drew, J. Mann, A. Thomas, *J. Chem. Soc. Perkin Trans. I* **1986**, 2279–2285.
- [11] This may be inferred from our isolation of closely related butenolide triflates: I. Kalvinsh, K.-H. Metten, R. Brückner, *Heterocycles* **1995**, *40*, 939–952.
- [12] This threefold sulfonylation/double-elimination reaction had been performed earlier in our laboratory with a *t*BuPh₂Si group in place of the *t*BuMe₂Si group: K.-H. Metten, I. Kalwinsh, R. Brückner, unpublished results.
- [13] W. C. Still, M. Kahn, A. Mitra, *J. Org. Chem.* **1978**, *43*, 2923–2925.
- [14] In earlier closely related deoxygenations (I. Kalvinsh, K.-H. Metten, R. Brückner, *Heterocycles* **1995**, *40*, 939–952) we used Pd(PPh₃)₄ and Me₃SnH in adoption of a procedure for standard enol triflates by W. J. Scott, J. K. Stille, *J. Am. Chem. Soc.* **1986**, *108*, 3033–3040.
- [15] Experimental details (except the work-up procedure) fashioned after a desilylation described by K. C. Nicolaou, S. P. Seitz, M. R. Pavia, N. A. Petasis, *J. Org. Chem.* **1979**, *44*, 4011–4013.
- [16] Method: a) D. B. Dess, J. C. Martin, *J. Org. Chem.* **1983**, *48*, 4155–4156; b) S. D. Meyer, S. L. Schreiber, *J. Org. Chem.* **1994**, *59*, 7549–7552.
- [17] Related observations: C. F. Ingham, R. A. Massy-Westrop, *Aust. J. Chem.* **1974**, *27*, 1491–1503; F. Goerth, A. Umland, R. Brückner, *Eur. J. Org. Chem.* **1998**, in press (issue 6); ref. [5].
- [18] L. Brandsma, *Preparative Acetylenic Chemistry*, Elsevier, Amsterdam, Oxford, New York, Tokyo, **1988**, pp. 53–54.
- [19] Method: P. L. Southwick, J. R. Kirchner, *J. Org. Chem.* **1962**, *27*, 3305–3308.
- [20] For cross-coupling reactions of iodoalkynes and vinylstannanes: G. J. Hollingworth, J. B. Sweeney, *Synlett* **1993**, 463–465.
- [21] Compound **15** was prepared from NaC≡CH and epichlorohydrin as a 90:10 *trans:cis* mixture (36%) following the procedure of L. Brandsma, H. D. Verkrujse, *Synthesis of Acetylenes, Allenes, Cumulenes*, Elsevier, Amsterdam, **1992**, pp. 78 (obtained 37–46% of 90:10–95:5 *trans:cis* mixtures).
- [22] We are indebted to Professor Angel R. de Lera (Universidad de Vigo, Spain) for communicating to us this procedure prior to publication.
- [23] We followed a general procedure for the conversion of alcohols into bromides by A. K. Mandal, S. W. Mahajan, *Tetrahedron Lett.* **1985**, *26*, 3863–3866.
- [24] Syntheses of conjugated phosphorus ylids and their Wittig reactions with conjugated aldehydes: P. Patel, G. Pattenden, *J. Chem. Soc. Perkin Trans. I* **1991**, 1941–1945.
- [25] M. Hesse, H. Meier, B. Zeeh, *Spektroskopische Methoden in der Organischen Chemie*, 4th ed., Thieme, Stuttgart, **1991**, p. 118.